Alvotech Shares Plunge to New 52-Week Low of $4.70
Alvotech, a small-cap pharmaceutical company, has reached a new 52-week low, reflecting a substantial decline in stock performance over the past year. Despite impressive growth in net sales and operating profit, the company faces financial challenges, including a negative book value and a high debt-to-equity ratio.
Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 4.70 as of November 4, 2025. This marks a significant decline, with the stock's performance over the past year reflecting a decrease of 66.6%. In contrast, the S&P 500 has shown a positive performance of 19.89% during the same period.The company's market capitalization stands at USD 2,463 million, and it currently has a price-to-earnings (P/E) ratio of 33.00. However, Alvotech's financial metrics indicate challenges, including a negative book value and a return on equity of -36.55%. The company's debt-to-equity ratio is reported at -5.66, suggesting difficulties in managing its debt obligations.
Despite a notable annual growth rate in net sales of 142.90% and operating profit growth of 48.15% over the last five years, Alvotech's overall financial health appears to be under pressure. The stock's performance has been below par, with a significant decline in value compared to its 52-week high of USD 13.70.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
